Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503346 | 1.00 | ALDH1A1 (0.49) | ALDH1A1THRBTSHRLMNACYP19A1 | |
| SCHEMBL13080335 | 0.95 | ALDH1A1 (0.53) | ALDH1A1THRBTSHRLMNACYP19A1 | |
| SCHEMBL12975815 | 0.93 | ALDH1A1 (0.55) | ALDH1A1THRBTSHRLMNA | |
| SCHEMBL26187807 | 0.93 | ALDH1A1 (0.55) | ALDH1A1THRBTSHRLMNA | |
| SCHEMBL12269715 | 0.88 | ALDH1A1 (0.60) | ALDH1A1THRBTSHRLMNA | |
| SCHEMBL496421 | 0.88 | ALDH1A1 (0.60) | ALDH1A1THRBTSHRLMNA | |
| SCHEMBL12604035 | 0.87 | ALDH1A1 (0.49) | ALDH1A1THRBTSHRLMNA | |
| SCHEMBL13080336 | 0.87 | ALDH1A1 (0.49) | ALDH1A1THRBTSHRLMNA | |
| SCHEMBL23493886 | 0.85 | ALDH1A1 (0.50) | ALDH1A1THRBTSHR | |
| SCHEMBL18309889 | 0.82 | ALDH1A1 (0.55) | ALDH1A1THRBTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023801-B2 | Polymerizable-compound-containing liquid crystal composition and liquid crystal display element using same | DIC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
| US-8663497-B2 | Liquid crystal composition comprising polymerizable compound, and liquid crystal display element using said liquid crystal composition | ADEKA CORPORATION (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8512597-B2 | Polymerizable optically active imide compound and polymerizable composition containing the compound | ADEKA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8283000-B2 | Liquid crystal composition containing polymerizable compound and liquid crystal display using the liquid crystal composition | ADEKA CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| US-8057701-B2 | Trifunctional (meth)acrylate compound and polymerizable composition containing same | ADEKA CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORPORATION (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20100328601-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL DISPLAY USING THE LIQUID CRYSTAL COMPOSITION | ADEKA CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | H1-4, XPO4, F12 | ALDH1A1 3300/4885THRB 4794/4885TSHR 3993/4885 |
| US-10023801-B2 | Polymerizable-compound-containing liquid crystal composition and liquid crystal display element using same | KLK3, LPXN, AR | ALDH1A1 3296/4885THRB 4725/4885TSHR 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.